Do you advocate for dose dense AC instead of every 3 week dosing in neoadjuvant TNBC as done in KEYNOTE 522?

Topics: Breast Cancer • Medical Oncology • Breast Cancer, Non-metastatic

Answer from: Medical Oncologist at Academic Institution

When giving neoadjuvant therapy for TNBC as given in the KEYNOTE-522 study, I prefer to administer dose dense AC (with growth factor support) + pembrolizumab (after completing weekly paclitaxel and carboplatin + pembrolizumab). While there has been no comparison of dose dense vs. q3week AC with this...

Comments

Medical Oncologist at SSM Health Medical Group
Are you bringing the patient back the following we...

Medical Oncologist at Warren Alpert Medical School of Brown University
For now, yes, I usually have the patient come in f...

Answer from: Medical Oncologist at Academic Institution

We utilize the regimen scheduled studied in KEYNOTE-522 with q3 week AC. Having given carbo/taxol-ddAC prior to the use of pembrolizumab, I find that the tolerance of AC chemotherapy and count recovery has been better with q3week schedule. Although prior studies have shown improvement of outco...

Related Questions